GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Steris PLC (NYSE:STE) » Definitions » Tax Expense

Steris (Steris) Tax Expense : $114 Mil (TTM As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is Steris Tax Expense?

Steris's tax expense for the months ended in Dec. 2023 was $38 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2023 was $114 Mil.


Steris Tax Expense Historical Data

The historical data trend for Steris's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Steris Tax Expense Chart

Steris Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.28 90.90 120.66 71.63 51.54

Steris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.01 8.16 34.12 33.81 38.34

Steris Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $114 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Steris  (NYSE:STE) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Steris Tax Expense Related Terms

Thank you for viewing the detailed overview of Steris's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Steris (Steris) Business Description

Traded in Other Exchanges
Address
5960 Heisley Road, Mentor, OH, USA, 44060
Steris is an Ireland-domiciled medical device company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its 2015 inversion to Ireland, the firm continues to derive roughly 70% of revenue from its U.S. operations, 10% from the United Kingdom, and the remaining 20% from other international regions.
Executives
Richard C Breeden director 100 SOUTH WACKER, SUITE 1800, CHICAGO IL 60606
Cynthia L Feldmann director 17 WINTHROP ROAD, WAYLAND MA 01778
Jacqueline B Kosecoff director 5960 HEISLEY ROAD, MENTOR OH 44060
Mohsen Sohi director C/O STERIS CORPORATION, 5960 HEISLEY ROAD, MENTOR OH 44060
Esther M. Alegria director 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Cary L Majors officer: VP, N America Com Operations 5960 HEISLEY ROAD, MENTOR OH 44060
John Adam Zangerle director, officer: Sr. VP, Gen Counsel, and Sec. 5960 HEISLEY ROAD, MENTOR OH 44060
Michael J Tokich director, officer: Sr. Vice Pres., CFO C/O STERIS CORP, 5960 HEISLEY RD, MENTOR OH 44060
Karen L Burton officer: VP, Controller & CAO 5960 HEISLEY ROAD, MENTOR OH 44060
Renato Tamaro officer: V.P. & Corporate Treasurer 5960 HEISLEY ROAD, MENTOR OH 44060
Andrew Xilas officer: SVP and GM, Dental 5960 HEISLEY ROAD, MENTOR OH 44060
Paul Edward Martin director C/O UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422
Julia Madsen officer: Senior VP, Life Sciences 5960 HEISLEY ROAD, MENTOR OH 44060
David B Lewis director
Rosebrough Walter M Jr officer: President & CEO 5960 HEISLEY ROAD, MENTOR OH 44060